GENZYME CEREZYME RECOMBINANT GCR WILL BE AVAILABLE IN LIMITED QUANTITIES
GENZYME CEREZYME RECOMBINANT GCR WILL BE AVAILABLE IN LIMITED QUANTITIES within the next month following its approval for Gaucher's disease on May 23, Genzyme announced May 24. Production of Cerezyme for the first year will be sufficient to treat approximately 120 Gaucher's disease patients. Patients eligible for treatment with Cerezyme will initially be limited to those participating in post-approval clinical trials who have not previously been treated with Ceredase. "The research has been designed in part to determine whether dosages can be lowered, thereby reducing the cost of therapy, without sacrificing effectiveness," Genzyme said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth